Sex hormones, insomnia, and sleep quality: subjective sleep in the first year of hormone use 143 Table 5.1. Linear mixed models used for the statistical analysis. Model Outcome Unadjusted Sleep outcome a. ~ measurement time point + (1|participant ID) + (1|center) Adjusted Sleep outcome a. ~ measurement time point + alcohol use + psychotropic medication use + (1| participant ID) + (1|center) Moderator ISI score b. ~ measurement time point * moderator + (1| participant ID) + (1|center) a. The following outcomes were tested: ISI score, PSQI score, TST, SOL and SE. b. The moderator models were only tested on the ISI scores, since the PSQI scores were only available at baseline and 12 months after GAHT. c. As displayed in results: reported hot flashes (yes/no), as displayed in supplementary materials: having undergone a mastectomy, using cycle regulation medication 3. Results 3.1. Demographic characteristics As displayed in Table 5.2, the median age in trans men was 23.2 years (IQR=20.4; 29.5). The majority of trans men did not use psychotropic medication (n=230, 87.8%) or drugs (n=154, 85.1%). At the start of GAHT use, long-acting intramuscular testosterone undecanoate was the most common form of prescribed testosterone (n=176, 67.2%) in trans men. The median age of trans women was 27.5 years old (IQR=22.8; 36.6), and most did not use psychotropic medication (n=156, 85.4%) or drugs (n=154, 84.3%). At the start of GAHT in the trans women, oral estradiol valerate was the most common form of prescribed estrogens (n=132, 72.1%) and CPA was the most common form of prescribed anti-androgens (n=151, 82.5 %). The resulting serum hormone values are also displayed in the supplementary materials. 3.2. Insomnia The ISI scores indicate that 55.9% of trans men report no insomnia at baseline, 35.5% show mild insomnia, 8.0% show moderate insomnia, and 0.5% show severe insomnia. ISI scores in trans women at baseline indicate that 60.0% of trans women report no insomnia, 31.4% show mild insomnia, 7.9% show moderate insomnia, and 0.7% show severe insomnia. After 12 months of GAHT, the insomnia scores in the trans men show that 55.1% report no insomnia, 36.4% report mild insomnia, 7.5% report moderate insomnia and no participant reports severe insomnia. After 12 months of GAHT in the trans women, ISI scores show that 63.8% of participants report
RkJQdWJsaXNoZXIy MTk4NDMw